Home / Products / Genome-edited Cells / FUNDC1 Knockout HEK293T Cell Line

FUNDC1 Knockout HEK293T Cell Line

Cat. No. ARG43865
Product Type:

In Stock Cell Lines

Species:

Homo sapiens (Human)

Tissue Source:

Kidney

Growth Properties:

Adherent

In stock
Request a Quote
Ask a Question

Short Description 🔒

The FUNDC1 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited cell line lacking expression of the FUNDC1 mitophagy receptor, based on the high-transfection human embryonic kidney HEK293T host. It enables precise dissection of hypoxia-induced mitochondrial autophagy, where FUNDC1 dephosphorylation by PGAM5 facilitates LC3 binding and mitochondrial recruitment. Key regulators include HIF-1??, CK2, and Src kinases. This knockout line supports research into cancer, neurodegeneration, and ischemia-reperfusion injury using techniques such as immunoblotting, fluorescence colocalization, and mitophagy flux assays. It is a robust system for validating therapeutic targets and exploring mitochondrial quality control mechanisms. Contact Ascent Research for further details.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Kidney
Growth Mode:
Adherent
Age:
Fetus
Sex of Donor:
Female
Derived From Site:
Fetal kidney
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
HEK293T
Gene Name:
FUNDC1
Gene Identifier:
NCBI Gene ID 3164

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up‑to‑date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description 🔒

The FUNDC1 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited human cell line with targeted disruption of the FUNDC1 gene, eliminating expression of the mitophagy receptor. This knockout model provides a stable loss-of-function system for dissecting FUNDC1-dependent mitochondrial quality control and hypoxia-induced autophagy.

The host HEK293T cell line, derived from human embryonic kidney epithelium, stably expresses SV40 large T antigen, enhancing episomal plasmid replication and recombinant protein expression. Their high transfection efficiency and robust growth make them a preferred host for gene function and signaling studies.

FUNDC1 localizes to the mitochondrial outer membrane, where it acts as a hypoxia-responsive mitophagy receptor. Under low oxygen, HIF-1?? upregulates FUNDC1, and PGAM5 dephosphorylates it at Ser13, promoting interaction with LC3B and GABARAP to drive autophagosomal recruitment. Normoxic conditions see CK2 and Src-mediated phosphorylation that inhibit LC3 binding, while BCL2L1 binding suppresses mitophagy. FUNDC1 also interfaces with mitochondrial dynamics proteins DRP1 and OPA1, the E3 ligase MARCH5, and kinase ULK1.

In the HEK293T background, this knockout cell line provides a clean system to dissect the molecular steps of hypoxia-induced mitophagy, free from endogenous FUNDC1 activity. HEK293T cells are responsive to hypoxic stimuli and are extensively used in signaling and metabolic studies, making this line particularly suitable for unraveling FUNDC1??s role in mitochondrial stress responses and cell survival. It is valuable for exploring how FUNDC1 integrates signals to control mitochondrial turnover, relevant to pathologies such as neurodegeneration, cancer, and ischemia-reperfusion injury.

Typical assays include immunoblotting to monitor FUNDC1 loss and LC3 lipidation, immunofluorescence for quantification of LC3 puncta colocalizing with mitochondrial markers, and flow cytometry using mt-Keima or mito-QC reporters to measure mitophagy flux. Seahorse-based mitochondrial stress tests and co-immunoprecipitation of the FUNDC1-LC3 complex further enable rigorous functional analyses. This knockout line is thus a powerful tool for target validation in drug discovery, mechanistic studies of mitochondrial quality control, and investigation of FUNDC1-associated signaling networks. For further technical details or custom applications, please contact Ascent Research.